ProteoDesign, a biotech spin-out from Princeton University developing personalized immunotherapies in cancer, today announced the successful closing of a 1.7M€ financing round. The company has a novel proprietary platform for protein engineering, discovered after more than 20 years of pioneering research in the field. Proceeds from the financing will be used to advance ProteoDesign immunotherapy candidates through preclinical development.
The financing round was led by existing investor Caixa Capital Risc and joined by an undisclosed private investor.
cloud technology axon
tuTECHÔ, empresa social que lucha contra el sinhogarismo en España, ...
Capital-Riesgo.es
Subscribe to our newsletter and stay up to date with the latest news and deals!
2013 © Capital-Riesgo.es - Site Developments SL. All Rights Reserved. Terms of Service | Privacy Policy
Articles
Directory